Phase 2 Breast Cancer Trial, Recruiting NCT07537673 Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Condition: Breast Cancer
Back to Breast Cancer

Phase 2 Breast Cancer Trial, Recruiting

NCT07537673
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 85 years old
  • People with breast cancer who are scheduled to receive a palliative treatment with the medicine trastuzumab deruxtecan
  • People whose general health and ability to carry out daily activities falls within an acceptable range, as measured by a standard medical scale (confirm with trial site)
  • People whose blood cell counts are within acceptable levels — including platelets, white blood cells, and neutrophils
  • People whose liver test results (bilirubin and transaminase levels) are within acceptable ranges
  • People who have no fluid build-up in the abdomen, no bowel blockage, normal blood clotting, and a blood protein (albumin) level of at least 30g/L
  • People whose liver function is rated as "Grade A" on a standard medical scoring system called Child-Pugh (confirm with trial site)
  • People whose kidney function is within an acceptable range, based on either a blood test or a calculated kidney filtering rate

Who may not be able to join:

  • People who have a local inflammation or infection around the outer ear
  • People who have a tendency to bleed or have blood clotting problems
  • People who have severe fluid build-up in the abdomen
  • People who have a bowel blockage
  • People experiencing a severe sudden rise in blood pressure or related brain complications
  • People with serious uncontrolled conditions such as severe infection or uncontrolled diabetes
  • People with serious heart or blood vessel conditions, including a stroke or heart attack within the past 6 months, poorly controlled high blood pressure, unstable chest pain, heart failure, or heart rhythm problems requiring medication
  • People with a history of, or signs of, central nervous system conditions — such as a primary brain tumour, uncontrolled epilepsy, any prior brain spread of cancer, or a history of stroke
  • People who have had an allergic reaction to any medicines used in this trial
  • People who are pregnant or currently breastfeeding
  • People with other diseases, complications from cancer spread, or conditions identified during examination that the treating doctor considers to make the trial medicines unsafe or unsuitable
  • People who are unwilling or unable to follow the requirements of the trial protocol

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 8617816190946

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
25 November 2025
Est. completion
1 November 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Proportion of patients experiencing nausea as assessed by NIC-CTC AE4.0

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov